Literature DB >> 3142562

Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial.

I Andersson1, K Aspegren, L Janzon, T Landberg, K Lindholm, F Linell, O Ljungberg, J Ranstam, B Sigfússon.   

Abstract

STUDY
OBJECTIVE: To determine whether mortality from breast cancer could be reduced by repeated mammographic screening.
DESIGN: Birth year cohorts of city population separately randomised into study and control groups.
SETTING: Screening clinic outside main hospital. PATIENTS: Women aged over 45; 21,088 invited for screening and 21,195 in control group.
INTERVENTIONS: Women in the study group were invited to attend for mammographic screening at intervals of 18-24 months. Five rounds of screening were completed. Breast cancer was treated according to stage at diagnosis. END POINT: Mortality from breast cancer.
MEASUREMENTS AND MAIN RESULTS: All women were followed up and classed at end point as alive without breast cancer, alive with breast cancer, dead from breast cancer, or dead from other causes. Cause of death was taken from national mortality registry and for patients with breast cancer was validated independently. Mean follow up was 8.8 years. Altogether 588 cases of breast cancer were diagnosed in the study group and 447 in the control group; 99 v 94 women died of all causes and 63 v 66 women died of breast cancer (no significant difference; relative risk 0.96 (95% confidence interval 0.68 to 1.35)). In the study group 29% more women aged less than 55 died of breast cancer (28 v 22; relative risk 1.29 (0.74 to 2.25)). More women in the study group died from breast cancer in the first seven years; after that the trend reversed, especially in women aged greater than or equal to 55 at entry. Overall, women in the study group aged greater than or equal to 55 had a 20% reduction in mortality from breast cancer (35 v 44; relative risk 0.79 (0.51 to 1.24)). OTHER
FINDINGS: In the study group 100 (17%) cancers appeared in intervals between screenings and 107 (18%) in non-attenders; 51 of these women died from breast cancer. Cancers classed as stages II-IV comprised 33% (190/579) of cancers in the study group and 52% (231/443) in the control group.
CONCLUSIONS: Invitation to mammographic screening may lead to reduced mortality from breast cancer, at least in women aged 55 or over.

Entities:  

Mesh:

Year:  1988        PMID: 3142562      PMCID: PMC1834636          DOI: 10.1136/bmj.297.6654.943

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  17 in total

1.  A case-control study of the efficacy of a non-randomized breast cancer screening program in Florence (Italy).

Authors:  D Palli; M R Del Turco; E Buiatti; S Carli; S Ciatto; L Toscani; G Maltoni
Journal:  Int J Cancer       Date:  1986-10-15       Impact factor: 7.396

Review 2.  Screening for breast cancer: a review.

Authors:  A B Miller
Journal:  Eur J Cancer Clin Oncol       Date:  1988-01

3.  Periodic breast cancer screening in reducing mortality from breast cancer.

Authors:  S Shapiro; P Strax; L Venet
Journal:  JAMA       Date:  1971-03-15       Impact factor: 56.272

4.  Reduction of breast cancer mortality through mass screening with modern mammography. First results of the Nijmegen project, 1975-1981.

Authors:  A L Verbeek; J H Hendriks; R Holland; M Mravunac; F Sturmans; N E Day
Journal:  Lancet       Date:  1984-06-02       Impact factor: 79.321

5.  Evaluation of screening for breast cancer in a non-randomised study (the DOM project) by means of a case-control study.

Authors:  H J Collette; N E Day; J J Rombach; F de Waard
Journal:  Lancet       Date:  1984-06-02       Impact factor: 79.321

Review 6.  False premises and false promises of breast cancer screening.

Authors:  P Skrabanek
Journal:  Lancet       Date:  1985-08-10       Impact factor: 79.321

7.  Radiation risk from mammography: is it clinically significant?

Authors:  S A Feig
Journal:  AJR Am J Roentgenol       Date:  1984-09       Impact factor: 3.959

8.  Breast cancer screening: a different look at the evidence.

Authors:  C J Wright
Journal:  Surgery       Date:  1986-10       Impact factor: 3.982

9.  Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare.

Authors:  L Tabár; C J Fagerberg; A Gad; L Baldetorp; L H Holmberg; O Gröntoft; U Ljungquist; B Lundström; J C Månson; G Eklund
Journal:  Lancet       Date:  1985-04-13       Impact factor: 79.321

10.  Survival in breast cancer diagnosed between mammographic screening examinations.

Authors:  L H Holmberg; L Tabar; H O Adami; R Bergström
Journal:  Lancet       Date:  1986-07-05       Impact factor: 79.321

View more
  152 in total

1.  Scientific foundation of mammographic screening is based on inconclusive research in Sweden.

Authors:  G Sjönell; L Stâhle
Journal:  BMJ       Date:  1999-07-03

Review 2.  Preventive health care, 2001 update: screening mammography among women aged 40-49 years at average risk of breast cancer.

Authors:  J Ringash
Journal:  CMAJ       Date:  2001-02-20       Impact factor: 8.262

3.  Does mammography save lives?

Authors:  John Hoey
Journal:  CMAJ       Date:  2002-04-30       Impact factor: 8.262

4.  How effective is screening for breast cancer?

Authors:  L Nyström
Journal:  BMJ       Date:  2000-09-16

Review 5.  Cancer screening.

Authors:  A Barratt; P Mannes; L Irwig; L Trevena; J Craig; L Rychetnik
Journal:  J Epidemiol Community Health       Date:  2002-12       Impact factor: 3.710

6.  Breast cancer screening: who should be included?

Authors:  A B Miller
Journal:  J Gen Intern Med       Date:  1990 Sep-Oct       Impact factor: 5.128

7.  Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study.

Authors:  Karsten Juhl Jørgensen; Peter C Gøtzsche
Journal:  BMJ       Date:  2004-01-17

Review 8.  Choosing quality of care measures based on the expected impact of improved care on health.

Authors:  A L Siu; E A McGlynn; H Morgenstern; M H Beers; D M Carlisle; E B Keeler; J Beloff; K Curtin; J Leaning; B C Perry
Journal:  Health Serv Res       Date:  1992-12       Impact factor: 3.402

9.  Screening with discrimination.

Authors:  H S Cuckle
Journal:  BMJ       Date:  1990-10-20

10.  Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer.

Authors:  Christine Y Lu; Fang Zhang; Anita K Wagner; Larissa Nekhlyudov; Craig C Earle; Matthew Callahan; Robert LeCates; Xin Xu; Dennis Ross-Degnan; J Frank Wharam
Journal:  Breast Cancer Res Treat       Date:  2018-05-12       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.